Inquiry Basket
EC1167 is the linker for EC1169 which is a PSMA-targeted tubulysin B-containing conjugate.
| Catalog Number | Size | Price | Quantity | ||
|---|---|---|---|---|---|
| BADC-01496 | -- | $-- | Inquiry |
EC1167 is a cutting-edge chemical linker designed to connect small molecule drugs with larger bioactive compounds, enhancing their therapeutic potential. In drug discovery, this linker serves as a critical component in the synthesis of drug conjugates, which are at the forefront of precision medicine. Drug conjugates utilize the specificity of targeting agents to deliver potent cytotoxic compounds directly to diseased cells, minimizing collateral damage to healthy tissue. As a versatile linker, EC1167 plays a pivotal role in stabilizing these conjugates while allowing for the controlled release of the drug payload upon reaching its target.
The design of EC1167 leverages advanced chemistry to address the challenges encountered in the development of drug conjugates, including stability, solubility, and bioavailability. It is engineered to endure systemic circulation, ensuring that the drug conjugates remain intact until they encounter their specific target. Once at the target site, EC1167 facilitates the selective release of the tubulysin B payload, a microtubule inhibitor, which is particularly effective against proliferating cancer cells. This precise mode of action underscores EC1167’s importance in enhancing the efficacy and safety profile of drug conjugates in oncology therapeutic strategies.
Moreover, EC1167 is integral to the efficacy of EC1169, a PSMA-targeted tubulysin B-containing conjugate. EC1169 utilizes EC1167 to specifically target and bind to the Prostate-Specific Membrane Antigen (PSMA) expressed on prostate cancer cells. By doing so, EC1167 not only enhances target specificity but also ensures that the cytotoxic effects of tubulysin B are confined to cancer cells, thus maximizing anti-tumor activity while minimizing off-target toxicity. This targeted approach is critical in developing treatments that offer greater clinical benefits with a reduced risk of side effects compared to conventional chemotherapy.
In the broader context of drug discovery, EC1167 exemplifies the innovation and precision that modern medicinal chemistry strives to achieve. The ability to create highly specific and effective drug conjugates opens new horizons for treating a range of diseases that were previously difficult to manage. As the field continues to evolve, linkers like EC1167 will remain central to developing next-generation therapeutics that harness the potential of targeted drug delivery systems. In summary, EC1167 not only advances the therapeutic capabilities of conjugated drugs but also represents a significant leap towards more personalized and effective healthcare solutions.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
